Cardiovascular Health

A recent study showed that long-term exposure to fine particulate outdoor air pollution is a key contributor to cardiovascular disease and death throughout the world, regardless of the income bracket of the various countries.

Collaboration between pharmacists and general practice teams improves patient care and increases savings.

A new heart valve combines the biocompatibility of a biological valve with the robustness of a mechanical one.

COVID-19 attacks the cardiovascular system and may exasperate preexisting heart conditions.

Current research has already found that CVD is among the most common pre-existing conditions among people who die from COVID-19.

Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.

The paper is an update to previous guidelines released by ACSM and the American Heart Association in 1998.

Data from a new analysis reinforces concerns surrounding the detrimental impact the novel osteoporotic therapy romosozumab can have on cardiovascular health.

Research shows that the over-prescribing of opioids for short term pain management is a widespread issue in the United States.

individuals with four or more depressive symptoms had a 20% increase in cardiovascular events and death.

Current treatment guidelines do not recommend the use of either drug in hospitalized patients with COVID-19 outside of clinical trials.

Reducing salt intake to a healthier level appears to be beneficial for the gut microbiome and blood pressure, especially in females with untreated hypertension, according to researchers at the Medical College of Georgia at Augusta University.

There has been more attention been paid to the pulmonary complications of COVID-19, with less attention being paid to the cardiovascular complications that can result in death or impairment.

This marks the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy in patients with a high cardiovascular risk but without a history of heart attack or stroke.

The work and expertise of a drug utilization pharmacist should be empowered and integrated earlier into a recall process.

Nearly 30% of the 2773 patients with COVID-19 received systemic coagulation during their time in the hospital.

The statement is one of the first from the AHA to focus on providing evidence-based strategies for parents and caregivers to create a healthy food environment for young children.

Evolocumab, when used with diet, can be used as monotherapy or in combination with other lipid-lowering agents for the prevention of cardiovascular events.

According to a study, men have higher concentrations of ACE2 in their blood than women, which may be a potential explanation for why men are more susceptible to COVID-19.

At the end of 5 years, the teens with either obesity, T2D, or high systolic blood pressure were significantly more likely to have thicker and stiffer carotid arteries, the main blood vessel that leads to the brain, according to the study.

A phase 3 trial showed a statistically significant and clinically meaningful decline in CV death or hospitalization from heart failure with dapagliflozin compared with placebo.

Lifestyle classes, or cardiac rehabilitation, are typically offered to heart attack patients unless the patient has a particular reason why it is not suitable for them.

Engaging in discussions with patients at high risk of complications from COVID-19 without seeming patronizing is an important skill that many pharmacists should practice.

The STRIP examined the benefits of promoting cardiovascular health by dietary counseling from infancy to early adulthood.

According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.

There continues to be a debate in the scientific community about the role that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers play in coronavirus disease 2019 infection.

According to the researchers, women living in rural areas have a higher rate of premature death compared with those who are in more urban areas.

Patients with cardiovascular disease who develop COVID-19 have a higher risk of mortality, according to a SCAI press release.

A protein, known as FOXO1, plays a critical role in heart damage resulting from treatment with the chemotherapy drug anthracycline.

There have been reports of patients with COVID-19 having ST-segment elevation (STE) and, even after invasive coronary angiography, continuing to show no signs of COVID-19.